Idea principal
In 89 Spanish men with moderate to severe sleep apnea and overweight or obesity, an 8-week weight-loss and lifestyle programme lowered the apnea-hypopnea index by 21.2 events/h, a between-group difference of -23.6 events/h (95% CI -28.7 to -18.5) versus CPAP-only usual care. The trial was open-label, small and male-only, so results may not apply to women or other populations.
Study design
Ensayo aleatorizado
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
Obesity is the leading cause of obstructive sleep apnea (OSA), yet the effects of weight loss and lifestyle change on OSA and related health problems remain uncertain. The authors tested an interdisciplinary programme in men who were already using continuous positive airway pressure (CPAP).
Población y método
Parallel-group, open-label randomized clinical trial (INTERAPNEA) at a hospital referral centre in Granada, Spain, April 2019 to October 2020. 89 men aged 18 to 65 years with moderate to severe OSA and a body mass index of 25 or greater, all on CPAP, were randomized to usual care (CPAP; n = 49) or an 8-week programme of nutritional behaviour change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation plus usual care (n = 40). The primary outcome was change in the apnea-hypopnea index (AHI) at 8 weeks and 6 months after the intervention. Secondary outcomes included body weight and composition, cardiometabolic risk and quality of life. Registration NCT03851653.
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1At 8 weeks, AHI fell by 21.2 events/h (51% reduction; 95% CI -25.4 to -16.9) in the intervention group versus a rise of 2.5 events/h (95% CI -2.0 to 6.9) in controls, a between-group difference of -23.6 events/h (95% CI -28.7 to -18.5).
- 2At 6 months after the intervention, the AHI reduction was 57% in the intervention group, with a between-group difference of -23.8 events/h (95% CI -28.3 to -19.3).
- 3No longer needing CPAP: 18 of 40 (45.0%) at the end of the programme and 21 of 34 (61.8%) at 6 months. Complete OSA remission: 6 of 40 (15.0%), then 10 of 34 (29.4%).
- 4Intervention versus control also showed larger changes in body weight (-7.1 kg vs -0.3 kg), fat mass (-2.9 kg vs 1.4 kg), blood pressure (-6.5 mm Hg vs 2.2 mm Hg) and Sleep Apnea Quality of Life Index (0.8 vs 0.1 points).
Límites e incertidumbre
- 1Only 89 men from a single hospital in Spain took part, so results may not apply to women, other ethnic groups or milder OSA.
- 2The trial was open-label, so participants and staff knew who received the programme.
- 3Follow-up numbers at 6 months (34 of 40 in the intervention group) are smaller than at baseline, and the abstract does not explain the missing participants.
- 4The programme combined several components, so the abstract cannot say which part produced the benefit. This reading is based on the abstract only.
Relevancia práctica
For men with sleep apnea who carry extra weight, a structured programme of weight loss, exercise, sleep habits and cutting alcohol and tobacco may improve apnea severity, although this was one small trial. It does not mean CPAP can be stopped on your own; any change in therapy should be guided by your sleep specialist.
Tus datos
If your wearable estimates breathing disturbances or blood oxygen, it can show nightly trends, but it is not a substitute for a sleep study that measures AHI. Track body weight and morning blood pressure weekly with the same scale and cuff, and share trends with your clinician.
Cómo interpretar la evidencia
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Importance
Obesity is the leading cause of obstructive sleep apnea (OSA); however, the effects of weight loss and lifestyle interventions on OSA and comorbidities remain uncertain.
Objective
To evaluate the effect of an interdisciplinary weight loss and lifestyle intervention on OSA and comorbidities among adults with moderate to severe OSA and overweight or obesity.
Design, setting, and participants
The Interdisciplinary Weight Loss and Lifestyle Intervention for OSA (INTERAPNEA) study was a parallel-group open-label randomized clinical trial conducted at a hospital-based referral center in Granada, Spain, from April 1, 2019, to October 23, 2020. The study enrolled 89 Spanish men aged 18 to 65 years with moderate to severe OSA and a body mass index (calculated as weight in kilograms divided by height in meters squared) of 25 or greater who were receiving continuous positive airway pressure (CPAP) therapy. The sole inclusion of men was based on the higher incidence and prevalence of OSA in this population, the differences in OSA phenotypes between men and women, and the known effectiveness of weight loss interventions among men vs women.
Interventions
Participants were randomized to receive usual care (CPAP therapy) or an 8-week weight loss and lifestyle intervention involving nutritional behavior change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation combined with usual care.
Main outcomes and measures
The primary end point was the change in the apnea-hypopnea index (AHI) from baseline to the intervention end point (8 weeks) and 6 months after intervention. Secondary end points comprised changes in other OSA sleep-related outcomes, body weight and composition, cardiometabolic risk, and health-related quality of life.
Results
Among 89 men (mean [SD] age, 54.1 [8.0] years; all of Spanish ethnicity; mean [SD] AHI, 41.3 [22.2] events/h), 49 were randomized to the control group and 40 were randomized to the intervention group. The intervention group had a greater decrease in AHI (51% reduction; change, -21.2 events/h; 95% CI, -25.4 to -16.9 events/h) than the control group (change, 2.5 events/h; 95% CI, -2.0 to 6.9 events/h) at the intervention end point, with a mean between-group difference of -23.6 events/h (95% CI, -28.7 to -18.5 events/h). At 6 months after intervention, the reduction in AHI was 57% in the intervention group, with a mean between-group difference of -23.8 events/h (95% CI, -28.3 to -19.3 events/h). In the intervention group, 18 of 40 participants (45.0%) no longer required CPAP therapy at the intervention end point, and 6 of 40 participants (15.0%) attained complete OSA remission. At 6 months after intervention, 21 of 34 participants (61.8%) no longer required CPAP therapy, and complete remission of OSA was attained by 10 of 34 participants (29.4%). In the intervention vs control group, greater improvements in body weight (change, -7.1 kg [95% CI, -8.6 to -5.5 kg] vs -0.3 kg [95% CI, -1.9 to 1.4 kg]) and composition (eg, change in fat mass, -2.9 kg [95% CI, -4.5 to -1.3 kg] vs 1.4 kg [95% CI, -0.3 to 3.1 kg]), cardiometabolic risk (eg, change in blood pressure, -6.5 mm Hg [95% CI, -10.3 to -2.6 mm Hg] vs 2.2 mm Hg [95% CI, -2.1 to 6.6 mm Hg]), and health-related quality of life (eg, change in Sleep Apnea Quality of Life Index, 0.8 points [95% CI, 0.5-1.1 points] vs 0.1 points [95% CI, -0.3 to 0.4 points]) were also found at the intervention end point.
Conclusions and relevance
In this study, an interdisciplinary weight loss and lifestyle intervention involving Spanish men with moderate to severe OSA and had overweight or obesity and were receiving CPAP therapy resulted in clinically meaningful and sustainable improvements in OSA severity and comorbidities as well as health-related quality of life. This approach may therefore be considered as a central strategy to address the substantial impact of this increasingly common sleep-disordered breathing condition.
Trial registration
ClinicalTrials.gov Identifier: NCT03851653.
Fuentes y atribución
Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity: The INTERAPNEA Randomized Clinical Trial.
Carneiro-Barrera A, Amaro-Gahete FJ, Guillén-Riquelme A, Jurado-Fasoli L, Sáez-Roca G, Martín-Carrasco C, Buela-Casal G, Ruiz JR.
JAMA network open · 2022-04-01
DOI: 10.1001/jamanetworkopen.2022.8212 ↗PubMed · 35452108 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
Exercise improved sleep-quality scores in adults 45 and older with sleep disorders
Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.
Journal of Exercise Science & Fitness
Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults
Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.
Sleep
Sleep extension cut daily energy intake by about 270 kcal in adults with overweight
In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.
JAMA Internal Medicine
Six hours or less of sleep at 50 and 60 linked to higher dementia risk
In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.
Nature Communications

